Dana Pizzuti - 10 Oct 2022 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role: Chief Development Officer
Signature: /s/ Marc Wilson, as attorney-in-fact
Issuer symbol: CRNX
Transactions as of: 10 Oct 2022
Net transactions value: $0
Form type: 4
Filing time: 11 Oct 2022, 16:35:55 UTC
Previous filing: 11 Oct 2022
Next filing: 03 Mar 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CRNX	Common Stock	Award	$0	+12,500		$0.000000	12,500	10 Oct 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CRNX	Stock Option (right to buy)	Award	$0	+230,000		$0.000000	230,000	10 Oct 2022	Common Stock	230,000	$16.89	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on March 30, 2023.
F2	The option is exercisable as follows: 25% of the shares subject to the option vest on September 30, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.